Affinage

KLF10

Krueppel-like factor 10 · UniProt Q13118

Length
480 aa
Mass
52.6 kDa
Annotated
2026-04-28
100 papers in source corpus 46 papers cited in narrative 46 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

KLF10 (TIEG1) is a TGFβ-inducible Krüppel-like zinc finger transcription factor that functions as a central integrator of TGFβ/BMP, Wnt, circadian, and metabolic signaling by binding GC-rich/Sp1 and GT-rich elements in target gene promoters to either repress or activate transcription (PMID:10506214, PMID:12804117). KLF10 represses target genes (Smad7, SLUG, EGFR, Bmal1, SREBP-1C, IL-9, C/EBPα) by recruiting HDAC1 or the H3K4 demethylase JARID1B/KDM5B, and activates others (Foxp3, TGFβRII, Runx2, Osterix, Pgc-1α, zDHHC7) through association with PCAF acetyltransferase or Lef1/β-catenin, with the choice between repression and activation governed by an N-terminal Sin3-HDAC interaction domain whose inactivation switches KLF10 to an activating mode (PMID:24944246, PMID:22025675, PMID:20863814, PMID:28249899, PMID:19602726). Protein stability and nuclear localization are controlled by opposing post-translational modifications: RAF-1 phosphorylation at Thr93 licenses PIN1-mediated degradation, AMPK phosphorylation at Thr189 stabilizes the protein, and Tyk2-mediated phosphorylation at Tyr179 triggers K27-linked ubiquitination that blocks nuclear entry, while Itch-mediated K63-linked ubiquitination enhances KLF10 transcriptional function (PMID:23994618, PMID:34869587, PMID:21471442, PMID:18278048). Through these mechanisms, KLF10 controls TGFβ signal amplification, regulatory T cell differentiation, bone formation and remodeling, circadian hepatic metabolism and gluconeogenesis, adipogenesis, epithelial-mesenchymal transition, and apoptosis via the mitochondrial ROS/caspase pathway (PMID:20385766, PMID:33378664, PMID:15657444, PMID:34402428, PMID:10573529).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 1997 Medium

    Establishing that KLF10 is not merely a TGFβ-responsive marker but a functional effector: overexpression was sufficient to induce apoptosis in TGFβ-sensitive epithelial cells, implicating KLF10 as a mediator of TGFβ growth-inhibitory signaling.

    Evidence Stable transfection and cell viability assays in PANC1 pancreatic cells

    PMID:9153278

    Open questions at the time
    • Endogenous loss-of-function not tested
    • Mechanism of apoptosis induction unknown
    • Generalizability to other cell types unclear
  2. 1999 High

    Defining the structural basis for KLF10 transcriptional repression and the apoptotic mechanism: three discrete N-terminal repression domains were mapped, and the apoptosis pathway was shown to proceed through ROS generation, mitochondrial depolarization, and caspase-3 activation.

    Evidence GAL4-based mutagenesis/reporter assays for repression domains; ROS, mitochondrial membrane potential, and caspase assays in Hep3B cells for apoptosis

    PMID:10506214 PMID:10573529

    Open questions at the time
    • Corepressor partners for each repression domain unidentified
    • Endogenous target genes mediating apoptosis unknown
  3. 2003 High

    Defining the DNA-binding specificity of KLF10: SELEX identified a GT-rich core consensus (5'-GGTGTG-3'), establishing that KLF10 recognizes GC/GT-rich elements distinct from but overlapping with canonical Sp1 sites.

    Evidence Iterative nitrocellulose filter binding/SELEX with mutagenesis validation and VP16 transcriptional assay

    PMID:12804117

    Open questions at the time
    • Genome-wide binding profile not determined
    • Relationship between GT-rich and GC-rich site usage in vivo unresolved
  4. 2005 High

    Loss-of-function evidence established KLF10 as essential for bone homeostasis: KLF10 KO osteoblasts failed to mineralize properly and showed altered RANKL/OPG ratio, while female KO mice developed osteopenia with reduced bone formation.

    Evidence TIEG1 knockout mouse with calvarial osteoblast culture, mineralization and co-culture assays; DXA, micro-CT, histomorphometry in congenic null mice

    PMID:15657444 PMID:18396127

    Open questions at the time
    • Gender-specific mechanism unexplained
    • Direct transcriptional targets mediating bone phenotype not yet mapped
  5. 2008 High

    KLF10 was placed at the center of regulatory T cell biology through two discoveries: Itch-mediated K63-linked ubiquitination enhances KLF10 to induce Foxp3, while IL-6/Tyk2-mediated K27-linked ubiquitination blocks KLF10 nuclear entry—establishing opposing ubiquitin codes that toggle Treg versus effector fate.

    Evidence Co-IP, ubiquitin-linkage-specific assays, KO mouse airway inflammation (Itch/K63); phosphorylation mapping, nuclear translocation assays, KO tumor studies (Tyk2/K27)

    PMID:18278048 PMID:21471442

    Open questions at the time
    • Deubiquitinase(s) reversing K63 or K27 chains unknown
    • Whether both ubiquitin modifications occur on the same KLF10 molecule unclear
  6. 2009 High

    KLF10 was shown to directly transactivate both TGFβ1 and Foxp3 promoters in CD4+ T cells, creating a positive feedback loop for TGFβ signaling; KLF10-deficient Tregs had impaired suppressor function rescuable by exogenous TGFβ1.

    Evidence KLF10 KO mouse, promoter transactivation assays, cytokine measurement, in vivo atherosclerosis model

    PMID:19602726

    Open questions at the time
    • Chromatin remodeling events at Foxp3 locus during KLF10 binding not characterized
    • Relative contribution of KLF10 versus other KLFs in Treg function undefined
  7. 2010 High

    KLF10 was integrated into the circadian clock hierarchy: CLOCK-BMAL1 drives circadian Klf10 expression via E-box elements, and KLF10 in turn represses Bmal1 transcription (forming a secondary feedback loop) and represses the gluconeogenic gene Pepck, linking the clock to hepatic glucose metabolism.

    Evidence ChIP for BMAL1 at Klf10 promoter, ChIP for KLF10 at Bmal1 GC boxes, KO mouse metabolic phenotyping, bioluminescence circadian assays

    PMID:20070857 PMID:20385766

    Open questions at the time
    • Full set of clock-controlled KLF10 target genes not mapped
    • Whether KLF10 feeds back to CLOCK protein levels unknown
  8. 2010 Medium

    Identification of corepressor partners for KLF10: JARID1B/KDM5B was shown to bind KLF10 repression domains and augment Smad7 repression, while HPV-16 E7 was found to target KLF10 for proteasomal degradation—revealing both physiological and pathological regulation of KLF10 repressor complexes.

    Evidence Co-IP and domain-binding assays for JARID1B; yeast two-hybrid and Co-IP with ubiquitination/degradation assays for E7

    PMID:20691807 PMID:20863814

    Open questions at the time
    • Whether JARID1B and HDAC1 co-occupy the same KLF10-target promoters simultaneously untested
    • HPV E7 interaction not validated by reciprocal endogenous Co-IP
    • E7-KLF10 interaction not confirmed in HPV-infected primary cells
  9. 2011 High

    KLF10 was shown to directly regulate key osteogenic (Runx2) and oncogenic (EGFR) targets by recruiting distinct chromatin-modifying complexes: KLF10 co-activates Runx2 through direct promoter binding and protein interaction, while it represses EGFR by recruiting HDAC1 to Sp1 sites, suppressing breast cancer metastasis.

    Evidence ChIP, Co-IP, domain mutagenesis, KO osteoblast rescue for Runx2; ChIP, Co-IP of KLF10-HDAC1, xenograft model for EGFR

    PMID:21559363 PMID:22025675

    Open questions at the time
    • Whether KLF10-Runx2 protein interaction is direct or bridged unknown
    • Full spectrum of HDAC1-dependent KLF10 target genes in breast cancer not defined
  10. 2013 High

    Post-translational control of KLF10 stability was elucidated: RAF-1 phosphorylates KLF10 at Thr93, which creates a binding motif for PIN1 prolyl isomerase, promoting KLF10 degradation—linking RAS-RAF signaling to TGFβ pathway attenuation.

    Evidence In vitro kinase assay, site-directed mutagenesis, yeast two-hybrid and Co-IP for PIN1, cycloheximide chase

    PMID:23994618

    Open questions at the time
    • E3 ligase mediating PIN1-dependent degradation not identified
    • Whether other MAPK pathway kinases phosphorylate Thr93 untested
  11. 2014 High

    The dual-mode chromatin switch mechanism of KLF10 was defined: an intact N-terminal Sin3-HDAC domain enforces repression of Foxp3, but when this domain is inactivated, KLF10 associates with PCAF acetyltransferase to activate Foxp3—explaining how a single transcription factor toggles between repression and activation at the same locus.

    Evidence ChIP, genome-integrated reporter assays, domain deletion/mutation, primary lymphocyte assays

    PMID:24944246

    Open questions at the time
    • Signal that inactivates the Sin3-HDAC domain in vivo not identified
    • Whether this toggle mechanism applies to non-immune targets unknown
  12. 2015 High

    KLF10 was established as a master regulator of TGFβ receptor expression in immune cells: direct binding to the TGFβRII promoter enhances receptor levels and Smad2 phosphorylation in both CD8+ T cells and macrophages, with KLF10 deficiency producing pro-inflammatory phenotypes.

    Evidence ChIP in CD8+ T cells and macrophages, KLF10 KO mouse with flow cytometry and cytokine ELISA, in vivo viral infection and bone marrow transfer

    PMID:25472963 PMID:26472224

    Open questions at the time
    • Whether KLF10 also regulates TGFβRI expression untested
    • Mechanism of histone H3 acetylation increase at TGFβRII promoter (which acetyltransferase?) unclear
  13. 2017 High

    Multiple parallel advances established KLF10 as an anti-EMT factor (repressing SLUG via HDAC1 recruitment), a Wnt pathway co-activator (interacting with Lef1/β-catenin in bone), a metabolic regulator (activating Pgc-1α for gluconeogenesis), and an amplifier of TGFβ signaling (repressing Smad7 at a defined GC-box).

    Evidence ChIP with HDAC1 co-recruitment and EMT metrics for SLUG; Co-IP with Lef1/β-catenin and Wnt reporter for Wnt; ChIP and adenoviral OE/KD in mice for Pgc-1α; ChIP with defined binding site mutagenesis for Smad7

    PMID:28108300 PMID:28201653 PMID:28249899 PMID:28836014

    Open questions at the time
    • Whether SLUG repression and Smad7 repression use the same HDAC1 complex unclear
    • Wnt co-activator function not tested outside osteoblast context
    • Relative importance of Pgc-1α versus Pepck repression for gluconeogenic output not resolved
  14. 2018 High

    KLF10 was positioned in the adipogenic transcriptional cascade: C/EBPβ induces KLF10 early in adipogenesis, and KLF10 then recruits HDAC1 to repress C/EBPα and PPARγ, establishing a temporal brake on differentiation.

    Evidence ChIP for C/EBPβ at KLF10 promoter and KLF10/HDAC1 at C/EBPα promoter, promoter deletion analysis, 3T3-L1 differentiation assay

    PMID:30026232

    Open questions at the time
    • Whether KLF10 also regulates later stages of adipogenesis unknown
    • In vivo adipose-specific KO phenotype not reported
  15. 2020 High

    Cell-specific KO demonstrated that T cell-intrinsic KLF10 controls systemic metabolism: CD4-specific KLF10 deletion caused obesity, insulin resistance, and fatty liver through impaired Treg mobilization linked to reduced mitochondrial respiration and PI3K-Akt-mTOR signaling, fully rescued by WT Treg transfer.

    Evidence CD4-specific KO mouse, adoptive transfer rescue, metabolic phenotyping, mitochondrial respiration assay

    PMID:33378664

    Open questions at the time
    • Direct KLF10 transcriptional targets controlling Treg metabolism not identified
    • Whether KLF10 in other immune subsets contributes to metabolic phenotype untested
  16. 2021 High

    Two stabilizing/destabilizing post-translational pathways and a new lipogenic mechanism were defined: AMPK phosphorylation at Thr189 stabilizes KLF10 to repress SREBP-1C and suppress lipogenesis, while KLF10 also activates zDHHC7 transcription to drive CD36 palmitoylation and hepatic lipid uptake in NASH; hepatocyte-specific KO confirmed KLF10 integrates circadian and sugar signals for energy metabolism.

    Evidence In vitro kinase assay with Thr189 mutagenesis, ChIP-chip, hepatocyte-specific KO NAFLD model for AMPK/SREBP-1C; transcriptomics, palmitoylation assay, diet-induced NASH model for zDHHC7/CD36; hepatocyte-specific KO circadian transcriptome for circadian integration

    PMID:34402428 PMID:34869587 PMID:35492028

    Open questions at the time
    • How AMPK-stabilized KLF10 represses SREBP-1C while also activating zDHHC7 (seemingly pro-lipogenic) is paradoxical and unresolved
    • Whether circadian KLF10 oscillation modulates AMPK phosphorylation unknown
  17. 2022 High

    KLF10 was identified as a direct repressor of IL-9 in CD4+ T cells via HDAC1 recruitment, with KLF10 deficiency driving IL-9-dependent perivascular fibrosis; separately, KLF10 represses HO-1 in vascular smooth muscle cells under high glucose.

    Evidence ChIP for KLF10 and HDAC1 at IL-9 promoter, CD4-specific KO with Ang II model and anti-IL-9 rescue, scRNA-seq; ChIP and reporter assay with ROS measurement for HO-1

    PMID:32738388 PMID:35440172

    Open questions at the time
    • Whether IL-9 repression uses the same Sin3-HDAC complex as other targets unclear
    • In vivo relevance of HO-1 repression to diabetic vascular disease not confirmed in KO models
  18. 2024 High

    Exercise-induced KLF10 expression was traced through a cAMP/PKA/CREB pathway to activation of fumarate hydratase 1 (Fh1), which reduces fumarate and H3K4me3 at lipogenic gene promoters, providing a mechanistic link between physical activity and NASH attenuation.

    Evidence Hepatocyte-specific KO and OE mice, treadmill exercise model, pathway inhibitors, Fh1 expression assay, H3K4me3 ChIP, NASH dietary model

    PMID:38615945

    Open questions at the time
    • Whether the Fh1-fumarate-H3K4me3 axis is the dominant mechanism or one of several remains unclear
    • Long-term exercise studies in KLF10 KO not performed

Open questions

Synthesis pass · forward-looking unresolved questions
  • Several key mechanistic questions remain: (1) genome-wide binding maps in primary tissues have not been reported, (2) the structural basis for the Sin3-HDAC versus PCAF coactivator switch is undefined, (3) how RAF-1/PIN1-mediated degradation versus AMPK-mediated stabilization are coordinated in real time is unknown, and (4) whether KLF10 PTM codes (phosphorylation, K27/K63-ubiquitination) are integrated combinatorially to control nuclear access and target selection has not been tested.
  • No genome-wide ChIP-seq or CUT&RUN in primary cells published
  • Structural model of KLF10-corepressor/coactivator toggle unavailable
  • Combinatorial PTM code logic untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 13 GO:0003677 DNA binding 10
Localization
GO:0005634 nucleus 4
Pathway
R-HSA-168256 Immune System 8 R-HSA-162582 Signal Transduction 7 R-HSA-1430728 Metabolism 6 R-HSA-1266738 Developmental Biology 5 R-HSA-4839726 Chromatin organization 4 R-HSA-5357801 Programmed Cell Death 4 R-HSA-9909396 Circadian clock 3
Partners
CTNNB1HDAC1ITCHKDM5BLEF1PCAFPIN1RUNX2

Evidence

Reading pass · 46 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 Overexpression of KLF10 (TIEG) in TGFβ-sensitive PANC1 pancreatic epithelial cells is sufficient to induce apoptosis, linking TGFβ-mediated signaling to regulation of epithelial cell growth. Stable transfection/overexpression, cell viability assays The Journal of clinical investigation Medium 9153278
1999 KLF10 (TIEG1)-induced apoptosis proceeds through generation of reactive oxygen species and loss of mitochondrial membrane potential, followed by caspase-3 activation and glutathione depletion; antioxidant trolox blocks this pathway. Overexpression in Hep3B cells, ROS measurement, mitochondrial membrane potential assay, caspase activity assay Hepatology Medium 10573529
1999 KLF10 (TIEG1) contains three conserved transcriptional repression domains (R1: 10 aa, R2: 12 aa, R3: ~80 aa) in its N-terminal region outside the zinc finger domain, functionally conserved between TIEG1 and TIEG2. Extensive mutagenesis, GAL4-based transcriptional reporter assays The Journal of biological chemistry High 10506214
2000 Overexpression of KLF10 in human osteosarcoma MG-63 cells mimics TGFβ action: increases alkaline phosphatase activity, decreases osteocalcin mRNA/protein, and decreases cell proliferation; TGFβ treatment adds no further effect. Stable transfection, gene expression analysis, cell proliferation assay The Journal of biological chemistry Medium 10816551
2003 KLF10 (TIEG/EGRα) binds a consensus GT-rich core sequence (5'-GGTGTG-3') as identified by iterative nitrocellulose filter binding and PCR selection from random oligonucleotide libraries; mutagenesis confirmed this core is necessary for binding. SELEX (systematic evolution of ligands by exponential enrichment), nitrocellulose filter binding, mutational analysis, VP16 fusion transcriptional assay DNA and cell biology High 12804117
2004 KLF10 (TIEG1) overexpression in oligodendroglial OLI-neu cells induces apoptosis via repression of Bcl-XL, activation of Smad consensus promoter, and reduction of inhibitory Smad7 promoter activity, thereby facilitating TGFβ-mediated cell death. Overexpression, apoptosis ELISA, DNA fragmentation, caspase-3 assay, luciferase reporter assays Journal of neuroscience research Medium 14743447
2005 KLF10 (TIEG1) expression in osteoblasts is required for BMP2-induced mineralization in vitro and for osteoblast support of osteoclast differentiation; KLF10 KO osteoblasts show decreased RANKL and increased OPG expression. TIEG1 knockout mouse, calvarial osteoblast culture, mineralization assay, co-culture osteoclast differentiation assay, gene expression analysis Molecular and cellular biology High 15657444
2007 KLF10 (TIEG-1) acts as an intermediary factor downstream of BMP2 that blocks N-Myc expression by occupying Sp1 sites in the Nmyc promoter, thereby opposing Shh-mediated proliferation in cerebellar granule cell precursors and inducing cell cycle arrest. Ectopic expression in cerebellar granular neuron precursors, promoter occupancy analysis, cell cycle analysis The Journal of biological chemistry Medium 17951258
2007 KLF10 (TIEG1) induces apoptosis through the mitochondrial pathway involving Bax and Bim upregulation, Bcl-2 and Bcl-XL downregulation, cytochrome c release, caspase-3 activation, and disruption of mitochondrial membrane potential in K562 leukemia cells. Overexpression, Western blot, mitochondrial membrane potential assay, cytochrome c release assay FEBS letters Medium 17659279
2008 The E3 ubiquitin ligase Itch associates with KLF10 (TIEG1) and promotes K63-linked (nonproteolytic) ubiquitination of KLF10; this modification enhances KLF10 function to cooperatively induce Foxp3 expression in TGFβ-treated T cells. Co-immunoprecipitation, ubiquitination assay, KO mouse studies, in vivo airway inflammation model Nature immunology High 18278048
2008 KLF10 is regulated as a VHL target gene and directly transactivates the TGFBI (BIGH3) promoter in renal clear cell carcinoma cells. Expression arrays, VHL-status cell lines, luciferase reporter assay Biochemical and biophysical research communications Medium 18359287
2008 KLF10 knockout mice (female) display a gender-specific osteopenic phenotype with decreased bone mineral content/density, reduced cortical bone, decreased trabecular number, and reduced bone formation rate, demonstrating an essential role in skeletal homeostasis. Congenic TIEG-null mouse, DXA, pQCT, micro-CT, 3-point bending tests, histomorphometry Bone High 18396127
2009 KLF10 directly transactivates both the TGFβ1 and Foxp3 promoters in CD4+ T cells, creating a positive feedback loop; KLF10-deficient T regulatory cells have reduced TGFβ1 expression and impaired suppressor function, rescuable by exogenous TGFβ1. KLF10 KO mouse, overexpression, promoter transactivation assays, cytokine measurement, in vivo atherosclerosis model The Journal of biological chemistry High 19602726
2010 KLF10 displays circadian expression in mouse liver driven by the CLOCK-BMAL1 heterodimer binding a conserved E-box in the Klf10 promoter; KLF10 KO mice show dysregulation of metabolic genes, postprandial/fasting hyperglycemia, and KLF10 directly represses the Pepck gluconeogenic gene promoter. KLF10 KO mouse, chromatin immunoprecipitation (BMAL1 recruitment), liver transcriptome profiling, glucose tolerance tests, luciferase reporter assays Molecular and cellular biology High 20385766
2010 KLF10 (TIEG1) represses Bmal1 gene transcription by binding to two juxtaposed GC boxes near the transcription initiation site; siRNA-mediated knockdown of TIEG1 causes period shortening in cellular bioluminescence circadian rhythms. ChIP, promoter reporter assays, siRNA knockdown, real-time bioluminescence assay Genes to cells High 20070857
2010 JARID1B/KDM5B (histone H3K4 demethylase) is a corepressor of KLF10 (TIEG1); the repression domains of KLF10 bind the C-terminus of JARID1B; JARID1B overexpression augments KLF10-mediated Smad7 repression, while JARID1B knockdown increases Smad7 mRNA levels. Co-immunoprecipitation, domain-binding assays, Smad7 reporter assay, siRNA knockdown Biochemical and biophysical research communications Medium 20863814
2011 IL-6-induced Tyk2-mediated phosphorylation of KLF10 at Tyr179 promotes non-canonical K27-linked polyubiquitination of KLF10, inhibiting its nuclear translocation and thereby suppressing TGFβ-induced regulatory T cell development. Phosphorylation mapping, ubiquitination assays (K27-linkage), nuclear translocation assays, KO mouse tumor studies Journal of immunology High 21471442
2011 KLF10 (TIEG1) directly binds and activates the Runx2 promoter through its zinc finger domain; KLF10 protein also co-immunoprecipitates and co-localizes with Runx2 protein, co-activating Runx2 transcriptional activity; the ubiquitin/proteasome pathway modulates this regulation. Transient transfection, chromatin immunoprecipitation, co-immunoprecipitation, co-localization assays, KO osteoblasts, adenoviral rescue PloS one High 21559363
2011 KLF10 suppresses EGFR transcription by directly binding the EGFR promoter and forming a complex with HDAC1 at Sp1 sites, leading to reduced histone acetylation and inhibition of breast cancer invasion and metastasis. ChIP, Co-immunoprecipitation (KLF10-HDAC1 complex), promoter reporter assay, overexpression/knockdown, xenograft model Molecular and cellular biology High 22025675
2011 KLF10 directly modulates transcription of BI-1 (Bax inhibitor-1) by binding its promoter in estrogen-responsive adenocarcinoma cells; KLF10 suppression of BI-1 increases cytosolic Ca2+ and triggers apoptosis downstream of estrogen signaling. ChIP-chip, promoter reporter assay, EMSA, siRNA knockdown, Ca2+ measurement The international journal of biochemistry & cell biology Medium 21262377
2012 KLF10 directly binds the CACCC element of the IL-12p40 promoter and inhibits its transcription in M-CSF-induced macrophages; KLF10 deficiency leads to upregulated IL-12p40 production upon LPS stimulation. ChIP, promoter reporter assay, KLF10 KO and overexpression, ELISA European journal of immunology High 23065757
2012 KLF10 dose-dependently activates p21WAF1/CIP1 transcription independently of p53 and Sp1 binding sites, functioning as a tumor suppressor; KLF10 KO mice show increased susceptibility to skin tumorigenesis after DMBA/TPA treatment. KO mouse tumor model, luciferase reporter assay, colony formation assay, KLF10 transfection Biochemical and biophysical research communications Medium 22349513
2013 KLF10 binds the proximal Sp factor binding site of the FGFR1 promoter, reduces Sp1 complex formation, and represses FGFR1 promoter activity and myoblast proliferation. Southwestern blot, EMSA, chromatin immunoprecipitation, promoter reporter assay, cell proliferation assay The Journal of biological chemistry High 23569208
2013 KLF10 protein stability is regulated by RAF-1-mediated phosphorylation at Thr93, which enables interaction with the prolyl isomerase PIN1 in a phosphorylation-dependent manner, promoting KLF10 protein degradation. In vivo and in vitro phosphorylation assays, yeast two-hybrid, site-directed mutagenesis, Co-IP, cycloheximide chase Biochimica et biophysica acta High 23994618
2014 KLF10 couples to two antagonistic chromatin-modifying complexes to regulate FOXP3 gene inducibility: an N-terminal Sin3-HDAC interacting domain represses FOXP3, while inactivation of this domain allows KLF10 to associate with PCAF histone acetyltransferase and induce FOXP3 transcription. Chromatin immunoprecipitation, genome-integrated reporter assays, domain deletion/mutation of KLF10, primary lymphocyte assays American journal of physiology. Regulatory, integrative and comparative physiology High 24944246
2014 KLF10 directly binds the TGFβRII promoter in CD8+ T cells to enhance its expression; KLF10-deficient CD8+ T cells show reduced TGFβRII surface expression and attenuated Smad2 phosphorylation following TGFβ1 stimulation. ChIP, KLF10 KO mouse, flow cytometry, Smad2 phosphorylation assay, in vivo viral infection model American journal of physiology. Cell physiology High 25472963
2015 KLF10 directly binds the TGFβRII promoter in colonic macrophages, enhancing TGFβRII gene expression via histone H3 acetylation; KLF10 KO macrophages show lower TGFβRII levels, attenuated Smad-2 phosphorylation, and a pro-inflammatory phenotype. ChIP, KLF10 KO mouse, histone acetylation assay, cytokine ELISA, bone marrow transfer American journal of physiology. Gastrointestinal and liver physiology High 26472224
2015 KLF10 transcriptionally activates the SEI-1 promoter, leading to increased SEI-1 and subsequently p21Cip1 expression in pancreatic cells; KLF10 deficiency in mice reduces pancreatic islet mass. ChIP-chip screening, promoter reporter assay, KLF10 KO mouse histology The international journal of biochemistry & cell biology Medium 25578559
2016 KLF10 acts as a transcriptional repressor of NPRA; KLF10 binding reduces NPRA expression, and KLF10-deficient mice show increased pulmonary inflammation and higher sensitivity to LPS/ovalbumin challenge. ChIP, promoter reporter assay, KLF10 KO mouse, in vivo inflammation model The international journal of biochemistry & cell biology Medium 27592451
2016 KLF10 (TIEG1) directly binds and activates the Osterix promoter through its zinc finger domain, mediating TGFβ- and BMP2-induced Osterix expression in osteoblasts; TIEG1 KO osteoblasts have decreased Osterix. ChIP, transient transfection, domain mutagenesis, KO mouse osteoblasts Biochemical and biophysical research communications High 26801561
2017 KLF10 represses SLUG/SNAI2 transcription by occupying GC-rich sequences in its promoter and recruiting HDAC1 to remove activating histone acetylation marks, thereby suppressing TGFβ-induced epithelial-to-mesenchymal transition. KLF10 depletion, ChIP, histone modification analysis, EMT assays (multiple metrics), lung adenocarcinoma specimens Cancer research High 28249899
2017 KLF10 directly represses Smad7 transcription by binding a GC-box/Sp1 site (-1392 to -1382) in the Smad7 promoter, thereby promoting Smad2 phosphorylation and TGFβ/Smad signaling in keloid fibroblasts. ChIP, luciferase reporter assay, siRNA knockdown, TIEG1 overexpression, Western blot The Journal of investigative dermatology High 28108300
2017 KLF10 activates Pgc-1α gene transcription by directly binding to its promoter region, thereby regulating hepatic gluconeogenesis; KLF10 overexpression increases gluconeogenic gene expression and blood glucose levels. Luciferase reporter assay, ChIP, adenovirus overexpression/knockdown in mice, glucose tolerance tests Diabetologia High 28836014
2017 KLF10 (TIEG1) modulates β-catenin sub-cellular localization by altering AKT and GSK-3β activity; KLF10 also physically interacts with and serves as a transcriptional co-activator for Lef1 and β-catenin in the canonical Wnt signaling pathway in bone. Co-immunoprecipitation, subcellular fractionation, AKT/GSK-3β activity assays, KO mouse osteoblasts, Wnt reporter Nucleic acids research High 28201653
2017 Loss of KLF10 in pancreatic ductal adenocarcinoma increases distant metastases through activation of SDF-1/CXCR4 and AP-1 pathways; targeting SDF-1/CXCR4 in KLF10-null PDAC suppresses progression. KLF10 conditional KO mouse (KrasG12D model), in vivo tumor studies, pathway analysis Oncogene Medium 28581520
2018 KLF10 is transcriptionally induced by C/EBPβ (which binds the KLF10 promoter) during early adipogenesis; KLF10 then recruits HDAC1 to the C/EBPα promoter, reducing histone H4 acetylation and repressing C/EBPα (and consequently PPARγ) transcription to delay adipogenic gene expression. ChIP, promoter deletion/mutation analysis, luciferase reporter assay, siRNA, 3T3-L1 differentiation assay The Journal of biological chemistry High 30026232
2019 KDM6A (histone lysine demethylase) upregulates KLF10 expression, which in turn increases KDM6A expression forming a positive feedback loop; KLF10 represses nephrin expression by binding its promoter and recruiting methyltransferase Dnmt1. ChIP, KDM6A and KLF10 KO mice, Dnmt1 recruitment assay, kidney injury measurements EMBO molecular medicine High 30948420
2019 Loss of Tieg1 (KLF10) in mice results in altered sarcomere organization, decreased mitochondrial number, reduced succinate dehydrogenase staining, decreased complex I, COX and citrate synthase activities in soleus muscle, and exercise intolerance. TIEG1 KO mouse, RNA-seq, electron microscopy, histochemistry, mitochondrial function assays, 31P NMR spectroscopy Acta physiologica High 31560161
2020 CD4+ T-cell-specific KLF10 KO mice develop obesity, insulin resistance, and fatty liver due to impaired CD4+ Treg mobilization; TKO Tregs show reduced mitochondrial respiration, glycolysis, and PI3K-Akt-mTOR signaling causing impaired chemotaxis; adoptive transfer of WT Tregs fully rescues the phenotype. CD4-specific KO mouse, adoptive transfer, metabolic phenotyping, mitochondrial respiration assay, PI3K-Akt-mTOR pathway analysis Cell reports High 33378664
2021 KLF10 transcriptionally activates zDHHC7 expression; zDHHC7-mediated palmitoylation of CD36 promotes its plasma membrane localization, driving hepatic lipid accumulation and inflammation in NASH. Transcriptomic analysis, hepatocyte-specific KO/overexpression, palmitoylation assay, CD36 membrane localization, diet-induced NASH mouse model EMBO reports High 35492028
2021 AMPK phosphorylates KLF10 at Thr189, stabilizing the protein; phosphorylated KLF10 binds the SREBP-1C promoter to repress its transcription and downstream lipogenesis; hepatic-specific KLF10 KO mice develop more severe NAFLD. In vitro kinase assay, phosphorylation-site mutagenesis, ChIP-chip, luciferase reporter assay, hepatic-specific KO mouse, NAFLD model Frontiers in molecular biosciences High 34869587
2021 KLF10 integrates circadian and sugar signaling in hepatocytes; loss of hepatocyte KLF10 reprograms the liver circadian transcriptome altering energy metabolism pathways; glucose/fructose induce Klf10 which mitigates glucose intolerance and hepatic steatosis. Hepatocyte-specific KLF10 KO, liver circadian transcriptome profiling, metabolic challenge assays eLife High 34402428
2022 KLF10 binds the IL-9 promoter and interacts with HDAC1 to inhibit IL-9 transcription in CD4+ T cells; KLF10 deficiency in T cells elevates IL-9, which activates fibroblast calcium mobilization and promotes perivascular fibrosis. ChIP (KLF10-IL-9 promoter, HDAC1 interaction), CD4-specific KO mouse, Ang II infusion model, anti-IL9 antibody rescue, scRNA-seq Circulation research High 35440172
2022 KLF10 negatively regulates HO-1 gene transcription by directly binding to its promoter in vascular smooth muscle cells exposed to high glucose, thereby increasing ROS generation. ChIP, dual-luciferase reporter assay, KLF10 OE/KD, ROS measurement Journal of ethnopharmacology Medium 32738388
2024 Exercise induces hepatic KLF10 expression through the cAMP/PKA/CREB pathway; KLF10 activates fumarate hydratase 1 (Fh1) expression, reducing fumarate accumulation and H3K4me3 marks on lipogenic gene promoters, thereby attenuating hepatocyte steatosis and NASH. Hepatocyte-specific KO and OE mice, treadmill exercise model, pathway inhibitors, Fh1 expression assay, H3K4me3 ChIP, NASH dietary model Metabolism: clinical and experimental High 38615945
2010 HPV-16 oncoprotein E7 physically interacts with KLF10 (TIEG1) by binding its C-terminus, promotes KLF10 ubiquitination and degradation via the proteasomal pathway, and attenuates KLF10-mediated apoptosis. Yeast two-hybrid, Co-immunoprecipitation, ubiquitination assay, apoptosis assay The international journal of biochemistry & cell biology Medium 20691807

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1997 Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. The Journal of clinical investigation 200 9153278
2008 The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nature immunology 147 18278048
1999 The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. Hepatology (Baltimore, Md.) 142 10573529
2017 LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma. Cell death & disease 135 28796257
1999 Three conserved transcriptional repressor domains are a defining feature of the TIEG subfamily of Sp1-like zinc finger proteins. The Journal of biological chemistry 105 10506214
2010 Functional role of KLF10 in multiple disease processes. BioFactors (Oxford, England) 99 20087894
2005 TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. Molecular and cellular biology 98 15657444
2010 Kruppel-like factor KLF10 is a link between the circadian clock and metabolism in liver. Molecular and cellular biology 97 20385766
2009 Kruppel-like factor KLF10 targets transforming growth factor-beta1 to regulate CD4(+)CD25(-) T cells and T regulatory cells. The Journal of biological chemistry 88 19602726
2021 Hypoxic tumour cell-derived exosomal miR-340-5p promotes radioresistance of oesophageal squamous cell carcinoma via KLF10. Journal of experimental & clinical cancer research : CR 87 33485367
2000 TIEG proteins join the Smads as TGF-beta-regulated transcription factors that control pancreatic cell growth. American journal of physiology. Gastrointestinal and liver physiology 78 10762604
2018 KLF10 as a Tumor Suppressor Gene and Its TGF-β Signaling. Cancers 75 29799499
2000 Overexpression of a nuclear protein, TIEG, mimics transforming growth factor-beta action in human osteoblast cells. The Journal of biological chemistry 70 10816551
2011 Klf10 and Klf11 as mediators of TGF-beta superfamily signaling. Cell and tissue research 69 21574058
2007 Role of TIEG1 in biological processes and disease states. Journal of cellular biochemistry 69 17729309
2004 Dual functions of transcription factors, transforming growth factor-beta-inducible early gene (TIEG)2 and Sp3, are mediated by CACCC element and Sp1 sites of human monoamine oxidase (MAO) B gene. The Journal of biological chemistry 61 15024015
2019 A KDM6A-KLF10 reinforcing feedback mechanism aggravates diabetic podocyte dysfunction. EMBO molecular medicine 60 30948420
2007 Bone morphogenetic protein 2 opposes Shh-mediated proliferation in cerebellar granule cells through a TIEG-1-based regulation of Nmyc. The Journal of biological chemistry 60 17951258
2011 TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. Molecular and cellular biology 54 22025675
2008 Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochemical and biophysical research communications 54 18359287
2007 TGFbeta inducible early gene-1 (TIEG1) and cardiac hypertrophy: Discovery and characterization of a novel signaling pathway. Journal of cellular biochemistry 52 16888812
2020 Deletion of KLF10 Leads to Stress-Induced Liver Fibrosis upon High Sucrose Feeding. International journal of molecular sciences 50 33396939
2017 Krüppel-like Transcription Factor KLF10 Suppresses TGFβ-Induced Epithelial-to-Mesenchymal Transition via a Negative Feedback Mechanism. Cancer research 50 28249899
2010 Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10. Biochemical and biophysical research communications 48 20863814
2016 Zinc supplementation induces CD4+CD25+Foxp3+ antigen-specific regulatory T cells and suppresses IFN-γ production by upregulation of Foxp3 and KLF-10 and downregulation of IRF-1. European journal of nutrition 47 27260002
2008 Estrogen-TGFbeta cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors. Journal of cellular biochemistry 45 17541956
2017 TIEG1 Represses Smad7-Mediated Activation of TGF-β1/Smad Signaling in Keloid Pathogenesis. The Journal of investigative dermatology 44 28108300
2008 TIEG-null mice display an osteopenic gender-specific phenotype. Bone 43 18396127
2020 KLF10 Deficiency in CD4+ T Cells Triggers Obesity, Insulin Resistance, and Fatty Liver. Cell reports 42 33378664
2011 Noncanonical K27-linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth. Journal of immunology (Baltimore, Md. : 1950) 38 21471442
2007 TIEG1 induces apoptosis through mitochondrial apoptotic pathway and promotes apoptosis induced by homoharringtonine and velcade. FEBS letters 38 17659279
2000 Cytokine-specific induction of the TGF-beta inducible early gene (TIEG): regulation by specific members of the TGF-beta family. Journal of cellular biochemistry 38 10861837
2013 Repression of myoblast proliferation and fibroblast growth factor receptor 1 promoter activity by KLF10 protein. The Journal of biological chemistry 37 23569208
2018 Krüppel-like factor 10 (KLF10) is transactivated by the transcription factor C/EBPβ and involved in early 3T3-L1 preadipocyte differentiation. The Journal of biological chemistry 36 30026232
2011 Klf10 induces cell apoptosis through modulation of BI-1 expression and Ca2+ homeostasis in estrogen-responding adenocarcinoma cells. The international journal of biochemistry & cell biology 36 21262377
2011 TIEG1/KLF10 modulates Runx2 expression and activity in osteoblasts. PloS one 36 21559363
2017 KLF10 transcription factor regulates hepatic glucose metabolism in mice. Diabetologia 34 28836014
2010 Transcriptional repressor TIEG1 regulates Bmal1 gene through GC box and controls circadian clockwork. Genes to cells : devoted to molecular & cellular mechanisms 31 20070857
2012 KLF10, transforming growth factor-β-inducible early gene 1, acts as a tumor suppressor. Biochemical and biophysical research communications 29 22349513
2007 The role of STAT, AP-1, E-box and TIEG motifs in the regulation of hepcidin by IL-6 and BMP-9: lessons from human HAMP and murine Hamp1 and Hamp2 gene promoters. Blood cells, molecules & diseases 29 17689119
2017 KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the KrasG12D p53flox/flox model. Oncogene 28 28581520
2015 Klf10 regulates odontoblast differentiation and mineralization via promoting expression of dentin matrix protein 1 and dentin sialophosphoprotein genes. Cell and tissue research 27 26310138
2014 Krüppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-β signaling in CD8+ T lymphocytes. American journal of physiology. Cell physiology 27 25472963
2004 TIEG1 facilitates transforming growth factor-beta-mediated apoptosis in the oligodendroglial cell line OLI-neu. Journal of neuroscience research 27 14743447
1998 TGFbeta-inducible early gene (TIEG) also codes for early growth response alpha (EGRalpha): evidence of multiple transcripts from alternate promoters. Genomics 27 9721211
2022 KLF10 promotes nonalcoholic steatohepatitis progression through transcriptional activation of zDHHC7. EMBO reports 26 35492028
2014 Differential coupling of KLF10 to Sin3-HDAC and PCAF regulates the inducibility of the FOXP3 gene. American journal of physiology. Regulatory, integrative and comparative physiology 25 24944246
2013 Destabilization of KLF10, a tumor suppressor, relies on thr93 phosphorylation and isomerase association. Biochimica et biophysica acta 25 23994618
2012 TGFβ-inducible early gene-1 (TIEG1) mutations in hypertrophic cardiomyopathy. Journal of cellular biochemistry 25 22234868
2016 Impact of TIEG1 Deletion on the Passive Mechanical Properties of Fast and Slow Twitch Skeletal Muscles in Female Mice. PloS one 24 27736981
2015 Krüppel-like factor KLF10 deficiency predisposes to colitis through colonic macrophage dysregulation. American journal of physiology. Gastrointestinal and liver physiology 24 26472224
2011 TIEG1 negatively controls the myoblast pool indispensable for fusion during myogenic differentiation of C2C12 cells. Journal of cellular physiology 23 20945337
2022 Perivascular Fibrosis Is Mediated by a KLF10-IL-9 Signaling Axis in CD4+ T Cells. Circulation research 22 35440172
2021 Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway. Journal of experimental & clinical cancer research : CR 22 34635142
2020 Salvia miltiorrhiza bunge exerts anti-oxidative effects through inhibiting KLF10 expression in vascular smooth muscle cells exposed to high glucose. Journal of ethnopharmacology 22 32738388
2022 Krüppel-like factor 10 (KLF10) as a critical signaling mediator: Versatile functions in physiological and pathophysiological processes. Genes & diseases 21 37396542
2017 TIEG1 modulates β-catenin sub-cellular localization and enhances Wnt signaling in bone. Nucleic acids research 21 28201653
2004 Gene structure and evolution of Tieg3, a new member of the Tieg family of proteins. Gene 21 14697507
2021 MicroRNA-26b-5p alleviates cerebral ischemia-reperfusion injury in rats via inhibiting the N-myc/PTEN axis by downregulating KLF10 expression. Human & experimental toxicology 20 33559506
2021 KLF10 integrates circadian timing and sugar signaling to coordinate hepatic metabolism. eLife 20 34402428
2020 KLF10 inhibits cell growth by regulating PTTG1 in multiple myeloma under the regulation of microRNA-106b-5p. International journal of biological sciences 20 32549754
2016 TIEG1 enhances Osterix expression and mediates its induction by TGFβ and BMP2 in osteoblasts. Biochemical and biophysical research communications 20 26801561
2012 Klf10 inhibits IL-12p40 production in macrophage colony-stimulating factor-induced mouse bone marrow-derived macrophages. European journal of immunology 20 23065757
2023 Inhibition of Klf10 Attenuates Oxidative Stress-Induced Senescence of Chondrocytes via Modulating Mitophagy. Molecules (Basel, Switzerland) 19 36770589
2023 Exosomal ITGB6 from dormant lung adenocarcinoma cells activates cancer-associated fibroblasts by KLF10 positive feedback loop and the TGF-β pathway. Translational lung cancer research 18 38205211
2021 Therapeutic Targeting of Nonalcoholic Fatty Liver Disease by Downregulating SREBP-1C Expression via AMPK-KLF10 Axis. Frontiers in molecular biosciences 18 34869587
2018 MicroRNA-19 restores vascular endothelial cell function in lower limb ischemia-reperfusion injury through the KLF10-dependent TGF-β1/Smad signaling pathway in rats. Journal of cellular biochemistry 18 29953651
2024 Hepatic Klf10-Fh1 axis promotes exercise-mediated amelioration of NASH in mice. Metabolism: clinical and experimental 17 38615945
2019 Novel role of Tieg1 in muscle metabolism and mitochondrial oxidative capacities. Acta physiologica (Oxford, England) 17 31560161
2017 TIEG1 deficiency confers enhanced myocardial protection in the infarcted heart by mediating the Pten/Akt signalling pathway. International journal of molecular medicine 17 28204828
2016 Klf10 deficiency in mice exacerbates pulmonary inflammation by increasing expression of the proinflammatory molecule NPRA. The international journal of biochemistry & cell biology 17 27592451
2008 Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: role of TGFbeta/BMP-6 and TIEG1 in chemotherapy escape. International journal of cancer 17 18798273
2007 Minor contribution of SMAD7 and KLF10 variants to genetic susceptibility of type 2 diabetes. Diabetes & metabolism 17 17931948
2015 KLF10 affects pancreatic function via the SEI-1/p21Cip1 pathway. The international journal of biochemistry & cell biology 16 25578559
2012 Transactivation of the TIEG1 confers growth inhibition of transforming growth factor-β-susceptible hepatocellular carcinoma cells. World journal of gastroenterology 16 22563190
2011 Drosophila TIEG is a modulator of different signalling pathways involved in wing patterning and cell proliferation. PloS one 16 21494610
2003 Nitric oxide-mediated upregulation of the TGF-beta-inducible early response gene-1 (TIEG1) in human fibroblasts by mRNA stabilization independent of TGF-beta. Free radical biology & medicine 16 12788480
2020 MCD diet-induced steatohepatitis generates a diurnal rhythm of associated biomarkers and worsens liver injury in Klf10 deficient mice. Scientific reports 15 32699233
2015 Discovery of small molecule inhibitors to Krüppel-like factor 10 (KLF10): implications for modulation of T regulatory cell differentiation. Journal of medicinal chemistry 15 25581017
2020 KLF10 is a modulatory factor of chondrocyte hypertrophy in developing skeleton. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 14 32144802
2016 Impact of TIEG1 on the structural properties of fast- and slow-twitch skeletal muscle. Muscle & nerve 14 27421714
2015 Effect of TIEG1 on apoptosis and expression of Bcl-2/Bax and Pten in leukemic cell lines. Genetics and molecular research : GMR 14 25867342
2010 Tieg1/Klf10 is upregulated by NGF and attenuates cell cycle progression in the pheochromocytoma cell line PC12. Journal of neuroscience research 14 20155803
2003 Identification and characterization of a consensus DNA binding element for the zinc finger transcription factor TIEG/EGRalpha. DNA and cell biology 14 12804117
2022 KLF10 deficiency in CD4+ T cells promotes atherosclerosis progression by altering macrophage dynamics. Atherosclerosis 13 36174463
2020 KLF10 is upregulated in osteoarthritis and inhibits chondrocyte proliferation and migration by upregulating Acvr1 and suppressing inhbb expression. Acta histochemica 13 32156482
2016 KLF10 Mediated Epigenetic Dysregulation of Epithelial CD40/CD154 Promotes Endometriosis. Biology of reproduction 13 27488034
2010 Possible role of TIEG1 as a feedback regulator of myostatin and TGF-beta in myoblasts. Biochemical and biophysical research communications 13 20171187
2022 KLF10 upregulates ACSM3 via the PI3K/Akt signaling pathway to inhibit the malignant progression of melanoma. Oncology letters 12 35497935
2021 Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR. Frontiers in cell and developmental biology 12 34805140
2019 miR-892b Inhibits Hypertrophy by Targeting KLF10 in the Chondrogenesis of Mesenchymal Stem Cells. Molecular therapy. Nucleic acids 12 31284128
2010 Molecular structure of tail tendon fibers in TIEG1 knockout mice using synchrotron diffraction technology. Journal of applied physiology (Bethesda, Md. : 1985) 12 20378701
2022 Knockout of KLF10 Ameliorated Diabetic Renal Fibrosis via Downregulation of DKK-1. Molecules (Basel, Switzerland) 11 35565995
2017 Klf10 Gene, a Secondary Modifier and a Pharmacogenomic Biomarker of Hydroxyurea Treatment Among Patients With Hemoglobinopathies. Journal of pediatric hematology/oncology 11 28085748
2002 Absence of mutations in the transforming growth factor-beta inducible early gene 1, TIEG1, in pancreatic cancer. Cancer letters 11 12065093
2024 Klf10 is involved in extracellular matrix calcification of chondrocytes alleviating chondrocyte senescence. Journal of translational medicine 10 38217021
2022 LINC00629, a KLF10-responsive lncRNA, promotes the anticancer effects of apigenin by decreasing Mcl1 stability in oral squamous cell carcinoma. Aging 10 36445338
2017 TIEG and estrogen modulate SOST expression in the murine skeleton. Journal of cellular physiology 10 29044507
2015 TIEG1 Inhibits Angiotensin II-induced Cardiomyocyte Hypertrophy by Inhibiting Transcription Factor GATA4. Journal of cardiovascular pharmacology 10 26252173
2010 The human papillomavirus-16 (HPV-16) oncoprotein E7 conjugates with and mediates the role of the transforming growth factor-beta inducible early gene 1 (TIEG1) in apoptosis. The international journal of biochemistry & cell biology 10 20691807